← All trials
NCT07076225
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 25, 2025
- Primary completion
- Jan 31, 2030
- Completion date
- Jul 31, 2030
- First posted
- Jul 22, 2025
- Last posted
- Jul 22, 2025
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shenzhen Third People's HospitalLead sponsor
- Shenzhen Third People's HospitalSponsor investigator
- Fudan UniversityCollaborator
- Capital Medical UniversityCollaborator
- Sichuan UniversityCollaborator
- Tsinghua UniversityCollaborator
- Huazhong University of Science and TechnologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.